Skip to content
2000
Volume 6, Issue 3
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

Objectives

The aim of the study was to review the existing data on traditional medicine in reducing the symptoms in COVID-19 patients with mild, moderate, and severe symptoms. We also investigated the adverse impact, patient outcome, source, and mode of action of traditional medicine. A brief comparison was made on adverse impacts and symptom alleviation of the commercially available drugs as well.

Methods

We utilized PubMed, Scopus, WHO Global Health Library (GHL), and Virtual Health Library (VHL) in order to choose the eligible studies for the systematic review between July and August 2022. From a total of 12,263 studies, after a series of screening, 285 articles were identified in the final sample. The methodological evaluation was carried out accordingly.

Results

There is a growing literature on the usage of traditional medicine for COVID-19. The majority of the studies have shown positive outcomes even though they were not carried out at diverse locations around the world. We identified that the majority (17.4%) of the traditional medicine was derived from plants. The average time in the disappearance of the symptoms was 8.8 days, whereas the disappearance of symptoms using conventional drugs (Remdesivir, Ivermectin, Tocilizumab, Baricitinib, Famotidine, Ensitrelvir and Molnupiravir) was around 12 days. The mode of action of traditional medicine was mostly the reduction of viral load (50%). In terms of the severity of the patients, most of the patients (37.5%) had mild symptoms. We also found that no major adverse impact was reported on administering the traditional medicine among the patients. Further, the majority of the study was carried out in the Asian region, mostly in China.

Conclusion

Apart from expanding the study to different regions of the world, to improve the quality of data, larger-scale clinical studies in the Asian region are required.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975284726240328044546
2024-04-04
2025-09-27

  • From This Site

    /content/journals/covid/10.2174/0126667975284726240328044546
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AlsenaniF. Potential natural candidates in the treatment of coronavirus infections.Saudi J. Biol. Sci.202128105704571310.1016/j.sjbs.2021.06.008 34127903
     [Google Scholar]
  2. WongA. LiX. LauS. WooP. Global epidemiology of bat coronaviruses.Viruses201911217410.3390/v11020174 30791586
     [Google Scholar]
  3. AliS. AlamM. KhatoonF. Natural products can be used in therapeutic management of COVID-19: Probable mechanistic insights.Biomed. Pharmacother.202214711265810.1016/j.biopha.2022.112658 35066300
     [Google Scholar]
  4. AsraniP. HasanG.M. SohalS.S. HassanM.I. Molecular basis of pathogenesis of coronaviruses: A comparative genomics approach to planetary health to prevent zoonotic outbreaks in the 21st century.OMICS2020241163464410.1089/omi.2020.0131 32940573
     [Google Scholar]
  5. AsraniP. EapenM.S. HassanM.I. SohalS.S. Implications of the second wave of COVID-19 in India.Lancet Respir. Med.202199e93e9410.1016/S2213‑2600(21)00312‑X 34216547
     [Google Scholar]
  6. RamadanN. ShaibH. Middle East respiratory syndrome coronavirus (MERS-CoV): A review.Germs201991354210.18683/germs.2019.1155 31119115
     [Google Scholar]
  7. AlsafiR.T. Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far.Can. J. Infect. Dis. Med. Microbiol.2022202211310.1155/2022/1156273 35992513
     [Google Scholar]
  8. ChanC. FosterS.T. ChanK.G. Repositioned drugs for COVID-19—the impact on multiple organs.SN Compr. Clin. Med.2021371484150110.1007/s42399‑021‑00874‑8 33898925
     [Google Scholar]
  9. SinghR. BeheraM. KumariN. Nanotechnology-based strategies for the management of COVID-19: Recent developments and challenges.Curr. Pharm. Des.202127414197421110.2174/1381612827666210830105459 34459371
     [Google Scholar]
  10. YimerG. EkuadziE. FasinuP. de MeloA.C. PillaiG.C. Traditional medicines for COVID-19: Perspectives from clinical pharmacologists.Br. J. Clin. Pharmacol.20218793455345810.1111/bcp.14981 34272755
     [Google Scholar]
  11. MooreN. HamzaN. BerkeB. UmarA. News from Tartary: An ethnopharmacological approach to drug and therapeutic discovery.Br. J. Clin. Pharmacol.2017831333710.1111/bcp.13042 27297624
     [Google Scholar]
  12. BalandrinM.F. KinghornA.D. FarnsworthN.R. Plant-derived natural products in drug discovery and development.ACS Symposium Ser.199353421210.1021/bk‑1993‑0534.ch001
     [Google Scholar]
  13. PaudyalV. SunS. HussainR. AbutalebM.H. HedimaE.W. Complementary and alternative medicines use in COVID-19: A global perspective on practice, policy and research.Res. Social Adm. Pharm.20221832524252810.1016/j.sapharm.2021.05.004 33992585
     [Google Scholar]
  14. YoungB. TanT.T. LeoY.S. The place for remdesivir in COVID-19 treatment.Lancet Infect. Dis.20200010.1016/S1473‑3099(20)30911‑7 33248473
     [Google Scholar]
  15. SkipperC.P. PastickK.A. EngenN.W. Hydroxychloroquine in nonhospitalized adults with early COVID-19.Ann. Intern. Med.2020173862363110.7326/M20‑4207 32673060
     [Google Scholar]
  16. PaudyalV. CadoganC. FialováD. Provision of clinical pharmacy services during the COVID-19 Pandemic: Experiences of pharmacists from 16 European Countries.Res. Social Adm. Pharm.202010.1016/j.sapharm.2020.11.017 33288420
     [Google Scholar]
  17. MirzaieA. HalajiM. DehkordiF.S. RanjbarR. NoorbazarganH. A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19).Complement. Ther. Clin. Pract.20204010121410.1016/j.ctcp.2020.101214 32891290
     [Google Scholar]
  18. ZumlaA. ChanJ.F.W. AzharE.I. HuiD.S.C. YuenK.Y. Coronaviruses — drug discovery and therapeutic options.Nat. Rev. Drug Discov.201615532734710.1038/nrd.2015.37 26868298
     [Google Scholar]
  19. TongX. LiA. ZhangZ. TCM treatment of infectious atypical pneumonia--a report of 16 cases.J. Trad. Chin. Med.2004244266269
     [Google Scholar]
  20. ZhangM.M. LiuX.M. HeL. Effect of integrated traditional Chinese and Western medicine on SARS: A review of clinical evidence.World J. Gastroenterol.200410233500350510.3748/wjg.v10.i23.3500 15526373
     [Google Scholar]
  21. VellingiriB. JayaramayyaK. IyerM. COVID-19: A promising cure for the global panic.Sci. Total Environ.202072513827710.1016/j.scitotenv.2020.138277 32278175
     [Google Scholar]
  22. BalachandarV. MahalaxmiI. KaavyaJ. COVID-19: Emerging protective measures.Eur. Rev. Med. Pharmacol. Sci.202024634223425 32271461
     [Google Scholar]
  23. MatthayM.A. AldrichJ.M. GottsJ.E. Treatment for severe acute respiratory distress syndrome from COVID-19.Lancet Respir. Med.20208543343410.1016/S2213‑2600(20)30127‑2 32203709
     [Google Scholar]
  24. DequinP.F. HemingN. MezianiF. Effect of hydrocortisone on 21-day mortality or respiratory support among critically Ill patients with COVID-19.JAMA2020324131298130610.1001/jama.2020.16761 32876689
     [Google Scholar]
  25. HermineO. MarietteX. TharauxP-L. Resche-RigonM. PorcherR. RavaudP. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia.JAMA Intern. Med.20201811324010.1001/jamainternmed.2020.6820 33080017
     [Google Scholar]
  26. KarkiR. SharmaB.R. TuladharS. Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes.Cell2021184114916810.1016/j.cell.2020.11.025 33278357
     [Google Scholar]
  27. KimM.S. AnM.H. KimW.J. HwangT.H. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.PLoS Med.20201712e100350110.1371/journal.pmed.1003501 33378357
     [Google Scholar]
  28. GangulyS. BakhshiS. Traditional and complementary medicine during COVID-19 pandemic.Phytother. Res.202034123083308410.1002/ptr.6828 32785960
     [Google Scholar]
  29. ZhaoZ. LiY. ZhouL. Prevention and treatment of COVID-19 using traditional chinese medicine: A review.Phytomedicine202015330810.1016/j.phymed.2020.153308 32843234
     [Google Scholar]
  30. ZhangD. ZhangB. LvJ-T. SaR-N. ZhangX-M. LinZ-J. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence.Pharmacol Res202015710488210.1016/j.phrs.2020.104882
     [Google Scholar]
  31. LuoX. NiX. LinJ. The add-on effect of Chinese herbal medicine on COVID-19: A systematic review and meta-analysis.Phytomedicine20218515328210.1016/j.phymed.2020.153282 32800699
     [Google Scholar]
  32. YinB. BiY.M. SunL. Efficacy of integrated traditional Chinese and Western medicine for treating COVID-19: A systematic review and meta-analysis of RCTs.Front. Public Health2021962270710.3389/fpubh.2021.622707 34307269
     [Google Scholar]
  33. JeonS.R. KangJ.W. AngL. LeeH.W. LeeM.S. KimT.H. Complementary and alternative medicine (CAM) interventions for COVID-19: An overview of systematic reviews.Integr. Med. Res.202211310084210.1016/j.imr.2022.100842 35308033
     [Google Scholar]
  34. Levine-TiefenbrunM. YelinI. AlapiH. Waning of SARS-CoV-2 booster viral-load reduction effectiveness.Nat. Commun.2022131123710.1038/s41467‑022‑28936‑y 35246560
     [Google Scholar]
  35. GandhiR.T. LynchJ.B. del RioC. Mild or Moderate Covid-19.N. Engl. J. Med.2020383181757176610.1056/NEJMcp2009249 32329974
     [Google Scholar]
  36. RichardsonS. HirschJ.S. NarasimhanM. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with covid-19 in the new york city area.JAMA2020323202052205910.1001/jama.2020.6775 32320003
     [Google Scholar]
  37. AnX. PengB. HuangX. Ludangshen oral liquid for treatment of convalescent COVID-19 patients: A randomized, double-blind, placebo-controlled multicenter trial.Chin. Med.20221714210.1186/s13020‑022‑00602‑x 35366928
     [Google Scholar]
  38. AritaR. OnoR. SaitoN. Refractory Chest Pain in Mild to Moderate Coronavirus Disease 2019 Successfully Treated with Saikanto, a Japanese Traditional Medicine.Tohoku J. Exp. Med.2022257324124910.1620/tjem.2022.J040 35598972
     [Google Scholar]
  39. Cervantes TrejoA. CastañedaI.D. RodríguezA.C. Hydrogen peroxide as an adjuvant therapy for COVID-19: A case series of patients and caregivers in the mexico city metropolitan area.Evid. Based Complement. Alternat. Med.2021202111210.1155/2021/5592042 34335827
     [Google Scholar]
  40. DesdianiD. FadilahF. SutartoA.P. The effects of melaleuca cajuput oil (Melaleuca cajuputi) herbal treatment on clinical, laboratory, and radiological improvement and length of hospital stay in COVID-19 patients.J. Appl. Pharm. Sci.202212212710.7324/JAPS.2022.120611
     [Google Scholar]
  41. HuK. GuanW. BiY. Efficacy and safety of lianhuaqingwen capsules, a repurposed chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.Phytomedicine202015324210.1016/j.phymed.2020.153242 33867046
     [Google Scholar]
  42. NatarajanS. AnbarasiC. SathiyarajeswaranP. Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: Findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India.Trials202122162310.1186/s13063‑021‑05583‑0 34526104
     [Google Scholar]
  43. ShanmugamK. NirmalaA. ParthibanP. Safety and efficacy of siddha medicine preparation in the management of COVID-19: A prospective randomised open label study.J. Ayurveda Integr. Med.202213310059710.1016/j.jaim.2022.100597 35677618
     [Google Scholar]
  44. ZengC. YuanZ. ZhuJ. Therapeutic effects of traditional Chinese medicine (Maxingshigan-Weijing Decoction) on COVID-19: An open-label randomized controlled trial.Integr. Med. Res.20211010078210.1016/j.imr.2021.100782 34660195
     [Google Scholar]
  45. ZhaoC. LiL. YangW. Chinese medicine formula huashibaidu granule early treatment for mild covid-19 patients: An unblinded, cluster-randomized clinical trial.Front. Med. (Lausanne)2021869697610.3389/fmed.2021.696976 34604251
     [Google Scholar]
  46. KageyamaY. AidaK. KawauchiK. Jinhua Qinggan granule, a Chinese herbal medicine against COVID 19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL 6 and IFN γ: An open label, single arm pilot study.World Academy of Sciences Journal202141210.3892/wasj.2021.137
     [Google Scholar]
  47. HsiehP.C. ChaoY.C. TsaiK.W. Efficacy and Safety of Complementary Therapy With Jing Si Herbal Tea in Patients With Mild-To-Moderate COVID-19: A Prospective Cohort Study.Front. Nutr.2022983232110.3389/fnut.2022.832321 35369061
     [Google Scholar]
  48. PingY.H. YehH. ChuL.W. The Traditional Chinese Medicine Formula Jing Guan Fang for Preventing SARS-CoV-2 Infection: From Clinical Observation to Basic Research.Front. Pharmacol.20221374443910.3389/fphar.2022.744439 35387343
     [Google Scholar]
  49. SrivastavaA. RengarajuM. SrivastavaS. Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients—a double-blind, placebo-controlled, clinical trial.Trials202122157010.1186/s13063‑021‑05478‑0 34454572
     [Google Scholar]
  50. WangZ. ChenX. LuY. ChenF. ZhangW. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.Biosci. Trends2020141646810.5582/bst.2020.01030 32037389
     [Google Scholar]
  51. ZhangK. TianM. ZengY. The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19.Complement. Ther. Med.20205210247310.1016/j.ctim.2020.102473 32951723
     [Google Scholar]
  52. FengG. ShiL. HuangT. Human umbilical cord mesenchymal stromal cell treatment of severe COVID-19 patients: A 3-month follow-up study following hospital discharge.Stem Cells Dev.2021301577378110.1089/scd.2021.0015 34044609
     [Google Scholar]
  53. PanattoD. OrsiA. BruzzoneB. Efficacy of the Sentinox spray in reducing viral load in mild COVID-19 and its virucidal activity against other respiratory viruses: Results of a randomized controlled trial and an in vitro study.Viruses2022145103310.3390/v14051033 35632774
     [Google Scholar]
  54. YangX. WangY. LiuY. Traditional Chinese medicine together with high-dose vitamin C improves the therapeutic effect of western medicine against COVID-19.Am. J. Transl. Res.2022141501510 35173870
     [Google Scholar]
  55. AngamoM.T. MohammedM.A. PetersonG.M. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: A systematic review and meta-analysis.Infection2021501274110.1007/s15010‑021‑01671‑0 34331674
     [Google Scholar]
  56. ChoongC.K.C. BelgerM. KochA.E. Comparative effectiveness of dexamethasone in hospitalized COVID-19 patients in the United States.Adv. Ther.202239104723474110.1007/s12325‑022‑02267‑2 35962234
     [Google Scholar]
  57. HasanM.J. RabbaniR. AnamA.M. Impact of high dose of baricitinib in severe COVID-19 pneumonia: A prospective cohort study in Bangladesh.BMC Infect. Dis.202121142710.1186/s12879‑021‑06119‑2 33962573
     [Google Scholar]
  58. BeigelJ.H. TomashekK.M. DoddL.E. Remdesivir for the Treatment of Covid-19 — Final Report.N. Engl. J. Med.2020383191813182610.1056/NEJMoa2007764 32445440
     [Google Scholar]
  59. ToroghiN. AbbasianL. NourianA. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: A three-arm randomized clinical trial.N. Engl. J. Med.20227422924010.1007/s43440‑021‑00341‑0
     [Google Scholar]
  60. MarconiV.C. RamananA.V. de BonoS. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.Lancet Respir. Med.20219121407141810.1016/S2213‑2600(21)00331‑3 34480861
     [Google Scholar]
  61. KangX. JinD. JiangL. Efficacy and mechanisms of traditional Chinese medicine for COVID-19: A systematic review.Chin. Med.20221713010.1186/s13020‑022‑00587‑7 35227280
     [Google Scholar]
  62. DiazG.A. ChristensenA.B. PuschT. Remdesivir and mortality in patients with COVID-19.Nephrol. Dial. Transplant.202174ciab69810.1093/cid/ciab698 34409431
     [Google Scholar]
  63. HorbyP. LimW.S. EmbersonJ.R. Dexamethasone in Hospitalized Patients with Covid-19.N. Engl. J. Med.2021384869370410.1056/NEJMoa2021436 32678530
     [Google Scholar]
  64. SelvarajV. FinnA. LalA. KhanM.S. Dapaah-AfriyieK. CarinoG.P. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials.EClinicalMedicine20224910148910.1016/j.eclinm.2022.101489 35677732
     [Google Scholar]
  65. SinghA.K. SinghA. SinghR. MisraA. Molnupiravir in COVID-19: A systematic review of literature.Diabetes Metab. Syndr.202115610232910.1016/j.dsx.2021.102329 34742052
     [Google Scholar]
  66. ConglyS.E. VarugheseR.A. BrownC.E. ClementF.M. SaxingerL. Treatment of moderate to severe respiratory COVID-19: A cost-utility analysis.Sci. Rep.20211111778710.1038/s41598‑021‑97259‑7 34493774
     [Google Scholar]
  67. Price for experimental COVID-19 treatment raises concerns.Available From: https://www.hsph.harvard.edu/news/hsph-in-the-news/price-for-experimental-COVID-19-treatment-raises-concerns/ 29024
  68. OhsfeldtR. KeltonK. KleinT. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.Clin. Ther.2021431118771893.e410.1016/j.clinthera.2021.09.016 34732289
     [Google Scholar]
  69. WangY. ZhangD. DuG. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial.Lancet2020395102361569157810.1016/S0140‑6736(20)31022‑9 32423584
     [Google Scholar]
  70. LimS.C.L. HorC.P. TayK.H. Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: The I-TECH randomized clinical trial.JAMA Intern. Med.2022182442643510.1001/jamainternmed.2022.0189 35179551
     [Google Scholar]
  71. ManomaipiboonA. PholtawornkulchaiK. PoopipatpabS. Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: A randomized, double-blind, placebo-controlled trial.Trials202223171410.1186/s13063‑022‑06649‑3 36028897
     [Google Scholar]
  72. BrennanC.M. NadellaS. ZhaoX. Oral famotidine versus placebo in non-hospitalised patients with COVID-19: A randomised, double-blind, data-intense, phase 2 clinical trial.Gut202271587988810.1136/gutjnl‑2022‑326952 35144974
     [Google Scholar]
  73. YotsuyanagiH. OhmagariN. DoiY. A Phase 2/3 Study of S-217622 in Participants with SARS-CoV-2 Infection (Phase 3 Part).Medicine (Baltimore)20231028e3302410.1101/2022.07.15.22277670
     [Google Scholar]
  74. AdlerU.C. AdlerM.S. PadulaA.E.M. Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study).J. Integr. Med.202220322122910.1016/j.joim.2022.03.003 35339397
     [Google Scholar]
  75. LocH.N. LanT.T.N. HuongD.T.L. Traditional Vietnamese medicine Kovir capsule in patients with mild COVID-19: A double-blind randomized controlled trial.Phytother. Res.20223672878288810.1002/ptr.7455 35695687
     [Google Scholar]
  76. KumarA. PrasadG. SrivastavS. GautamV.K. SharmaN. Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study.medRxiv202010.1101/2020.09.20.20198515
     [Google Scholar]
  77. KannanM. SathiyarajeswaranP. SasikumarD. Safety and efficacy of a Siddha Medicine fixed regimen for the treatment of asymptomatic and mild COVID-19 patients.J. Ayurveda Integr. Med.202213310058910.1016/j.jaim.2022.100589 35634543
     [Google Scholar]
  78. Miake-LyeI.M. HempelS. ShanmanR. ShekelleP.G. What is an evidence map? A systematic review of published evidence maps and their definitions, methods, and products.Syst. Rev.2016512810.1186/s13643‑016‑0204‑x 26864942
     [Google Scholar]
  79. ColquhounH.L. LevacD. O’BrienK.K. Scoping reviews: Time for clarity in definition, methods, and reporting.J. Clin. Epidemiol.201467121291129410.1016/j.jclinepi.2014.03.013 25034198
     [Google Scholar]
/content/journals/covid/10.2174/0126667975284726240328044546
Loading
The Potential of Traditional Medicine in Combating COVID-19: A Systematic Review and Meta-Analysis
Coronaviruses 6, E040424228650 (2025); https://doi.org/10.2174/0126667975284726240328044546
/content/journals/covid/10.2174/0126667975284726240328044546
/content/journals/covid/10.2174/0126667975284726240328044546
Loading

Data & Media loading...

Supplements

PRISMA checklist and Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): COVID-19; immunotherapy; MERS-CoV; SARS-CoV; therapeutic plant; traditional medicine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test